Middle East And Africa Underactive Bladder Market
市场规模（十亿美元）
CAGR :
% 
USD
1.50 Billion
USD
1.97 Billion
2025
2033
 Forecast Period |
2026 –2033 |
 Market Size (Base Year) |
USD 1.50 Billion |
 Market Size (Forecast Year) |
USD 1.97 Billion |
 CAGR |
% |
| Major Markets Players |
|
中东和非洲低活性Bladder市场,按类型(药物疗法、外科手术方法、排泄物辅助装置、化粪池和基因治疗)、管理路线(Oral、Purner等)、疾病类型(神经致病性低活性与非神经致病性低活性Bladder)、分销渠道(医院药房、零售药店等) 2033年工业趋势和预测
中东和非洲市场概况
中东和非洲膀胱不足市场的价值2025年15亿美元预计将达到到2033年达到19.7亿美元,生长在一个2026年至2033年的CAGR为3.5%本区域神经病和非神经病膀胱病日益普遍,老年病人口不断增加,对尿道功能障碍的早期诊断和治疗的认识也日益提高。
糖尿病、帕金森病、脊髓损伤和多发性硬化症等慢性病的负担日益加重,这大大加剧了中东和非洲国家膀胱功能不足的发病率。 此外,改善保健基础设施、增加保健开支和扩大泌尿道护理的机会,都鼓励采用先进的药理疗法、神经调节装置和最低侵入性治疗程序。 增加对专科医院和康复中心的投资,以及更加重视盆腔保健和泌尿道疾病管理,进一步支持了整个区域的市场扩张。
主要市场趋势和见解
- 沙特阿拉伯主导了中东和非洲活动不足的膀胱市场,2025年收入份额最大,为34.28%,辅以强有力的保健基础设施发展、泌尿道护理投资增加,以及越来越多地采用先进的泌尿障碍治疗办法。
- 药疗部分在2025年占据了46.13%的市场主导地位,其驱动力是广泛临床采用尿道保留和膀胱活性不足的一线治疗.
- 南非预计将是2026年至2033年增长最快的国家市场,CAGR为4.8%,其推动力是改善获得保健服务的机会,提高对泌尿道疾病的认识,增加对诊断和康复服务的投资。
- 硬细胞和基因疗法是增长最快的类型,预计CAGR为5.4%,反映出对膀胱肌肉和神经恢复再生医学方法的兴趣激增。
- 口服部分主导了2025年行政类别的路线,收入份额为57.89%,主导者是病人偏好、管理便利和长期管理膀胱不活跃情况的处方率高。
- 神经诱导性低活性布拉德占市场52.44%,而偏好的是与糖尿病有关的神经病、脊髓损伤、帕金森病和多发性硬化症等神经病的高发率。
- 父母部分是行政类别增长最快的渠道,由于在重症和住院病例中越来越多地使用可注射疗法,该类别为5.1%。
市场大小和预测
- 全球市场价值(2025):1.5亿美元
- 预期市场价值(2033年):1.97亿美元
- CAGR(2026-2033年):3.5%
- 2025年主要区域:沙特阿拉伯
- 最快增长区域:南非
报告范围和范围中东和非洲
|
属性 |
中东和非洲市场透视 |
|
覆盖部分 |
|
|
涵盖国家 |
中东和非洲 沙特阿拉伯 · 美国 南非 • 埃及 • 以色列 中东其他地区和非洲 |
|
关键市场玩家 |
• 妇女阿斯泰拉斯制药公司(日本) • 妇女波士顿科学公司(美国). • 妇女科洛普拉斯公司(丹麦) • 妇女召集组 PLC(吴. • 妇女厨师(美国). 霍利斯特公司(美国) B. Braun SE(德国) · 美敦尼克(爱尔兰) Teleflex公司(美国) 健康保健(瑞典) · 劳工医疗技术公司(加拿大) · 辉瑞公司(美国) • AbbVie公司(美国) · UroMems(法国) Axonics股份有限公司(美国) · C.R.Bard, Inc.(美国) * 奥林匹斯公司(日本) Fresenius医疗协会(德国) · Cogentix医疗公司(美国) · BD(美国) |
|
市场机会 |
越来越多地采用圣体神经调节和可植入的膀胱刺激装置 增加对再生医学和干细胞膀胱疗法的临床研究 扩大家用导管产品和远程泌尿监测解决方案 |
|
添加数据信息集的值 |
除了对市场价值、增长率、分割、地理覆盖和主要角色等市场假设的深刻见解外,由数据桥市场研究编写的市场报告还包括深入的专家分析、病人流行病学、管道分析、定价分析和监管框架。 |
中东和非洲
趋势:日益采用高级泌尿治疗和提高认识方案
中东和非洲国家的保健提供者越来越多地对活动不足的膀胱采用先进的诊断和治疗方法,同时开展提高认识的运动并增加获得泌尿科保健服务的机会。 数字空气动力学测试、最低侵入性程序以及神经调节疗法的结合正在提高诊断的准确性和病人的结果。 医院和专科诊所也注重结构化膀胱康复方案,以解决与衰老有关的泌尿功能障碍和神经致病膀胱病例,而远程医疗平台正在扩大偏远地区的后续护理。 例如,沙特阿拉伯的主要三级医院越来越多地采用神经学相关泌尿道,以改善早期诊断和膀胱长期管理结果。
中东和非洲
关键市场驱动器:慢性神经病和内分泌紊乱症增加负担
中东和非洲国家的糖尿病、多发性硬化症、帕金森病和脊髓损伤发病率不断上升,这在很大程度上推动了对膀胱诊断和治疗不足办法的需求。 这些病症与神经致性膀胱功能障碍密切相关,导致泌尿科和康复中心的病人量增加. 扩大保健基础设施和增加对专科护理设施的投资,进一步支持早期发现和长期疾病管理。 例如,南非的公共和私人保健系统正在目睹越来越多的与糖尿病有关的神经病病例需要膀胱功能失调管理疗法。
主要限制/挑战:获得专门排尿护理和高治疗费用的机会有限
在中东和非洲活动不足的膀胱市场,一个主要制约因素是一些低收入和农村地区专门泌尿服务和先进诊断设备供应有限。 与神经调节装置、长期药物疗法和最低侵入性程序有关的高成本进一步限制了患者获得最佳治疗选择的机会。 此外,缺乏训练有素的泌尿科医生以及保健基础设施的发展不平衡,造成各国诊断和治疗方面的差异。 例如,尼日利亚的几个农村保健中心仍然依靠基本的症状治疗,因为得不到先进的空气动力学检测和专家咨询服务。
主要市场机会:扩大高级治疗和数字泌尿护理解决方案
中东和非洲活动不足的膀胱市场通过扩大先进治疗方式,如神经调节、再生医学和最低侵入性外科手术程序,提供了巨大的增长机会。 增加对医院基础设施和专科泌尿科中心的投资,正在为采用创新的膀胱功能失调管理办法创造一个有利的环境。 此外,数字保健平台、远程病人监测和人工智能辅助诊断工具的整合正在改善城市和半城市人口的早期发现和长期疾病管理结果。 例如,在阿拉伯联合酋长国,主要的保健网络正在越来越多地部署智能泌尿科诊所,这些诊所将数字诊断与个性化膀胱康复方案结合起来,以提高治疗效率和病人的合规性。
中东和非洲
中东和非洲活动不足的膀胱市场按类型、管理路线、疾病类型和分配渠道划分。
- 按类型
根据类型,中东和非洲活动不足的膀胱市场被划分为药物疗法、外科手术方法、尿道辅助装置以及干细胞和基因疗法。 2025年,药用治疗部分占了46.13%的市场份额,因为它被广泛作为泌尿和膀胱活性不足的一线治疗。 这些疗法由于易于获得、临床疗效既定以及治疗费用相对低于先进的干预措施而得到广泛青睐。 医院和诊所经常为神经致病和非神经致病者开具胆碱剂、甲状腺阻塞剂和综合药物药剂。 尿道功能障碍诊断率的提高进一步支持了整个区域的药物使用。 该部分还受益于扩大药物销售网络和改善新兴经济体的保健服务。
由于对膀胱肌肉和神经恢复的再生医学方法越来越感兴趣,预计Stem细胞和基因治疗部分在2026年至2033年的CAGR增长最快,为5.4%。 这些疗法旨在解决膀胱功能障碍的根源,而不仅仅是症状管理。 在高级泌尿道护理方面加强临床试验和研究合作,正在支持分科扩展。 中东一些国家对生物技术基础设施的投资正在进一步加快采用。 由于严重神经致病病例的临床需求未得到满足,该部分也越来越吸引人。 然而,高昂的成本和有限的可用性目前限制了广泛使用。
- 按行政路线分列
根据管理路线,市场分为口述,亲述等. 口服部分在2025年占据了市场主导地位,占比为57.89%,其驱动力是病人偏好、管理便利、以及长期管理膀胱不良情况的处方率高。 口服药物如胆碱兴奋剂和甲状腺阻塞剂被广泛用作医院和门诊场所的一线疗法. 这些药物与可注射治疗相比,提供了方便、更好的遵守和较低的程序风险。 扩大药店网络和改善药品供应进一步加强了部门支配地位。 继续采用经改进的口服制剂也加强了对治疗的坚持。 该部门受益于长期泌尿功能障碍病例的长期管理要求。
由于在重症和住院病例中越来越多地使用可注射疗法,父母部分在2026年至2033年的CAGR增长最快,为5.1%。 口服药物不能充分改善膀胱功能时,往往使用这些治疗方法。 神经致病性膀胱病的住院率上升,支持了对注射用药的需求。 药物运载系统和可控制释放注射制剂的进展正在进一步改善临床结果。 专门泌尿科中心越来越多的收养也促进了增长。 然而,更高的程序复杂性和费用仍然是限制因素。
- 按疾病类型
根据疾病类型,市场被分入神经致病性活性不足的膀胱和非神经致病性活性不足的膀胱. 神经诱导性低活性布拉德部分在2025年占据了52.44%的市场份额,原因是与糖尿病有关的神经病、脊髓损伤、帕金森病和多发性硬化症等神经系统疾病发病率很高。 这些病症严重影响了膀胱神经信号,导致临床诊断率较高. 整个区域的医院越来越注重神经-泌尿综合护理途径。 人口不断老化也导致发病率上升。 对长期管理疗法的强烈需求进一步加强了部门主导地位。 这部分人受益于三级护理中心的认识提高和诊断能力的提高。
2026至2033年间,由于与衰老、手术后并发症和代谢失调有关的病例增加,非神经诱发性低活性血压板部分的CAGR增长最快,为4.9%。 提高病人和医生的认识正在提高非神经性膀胱功能障碍的检测率。 与生活方式相关的风险因素,如肥胖和定居行为,也促进了分块生长. 扩大门诊泌尿科服务,进一步支持早期诊断和治疗. 对药物管理和康复疗法的需求正在稳步增加。 然而,农村地区的诊断不足仍然是一个挑战。
- 按发行频道
根据配送渠道,将市场分入医院药房,零售药房等. 2025年,医院药房部分占市场主导份额为57.36%,原因是第三护理医院的病人流入量大,以及处方疗法的供应量大。 医院仍然是需要专家监督的神经病和严重的泌尿功能障碍病例的主要治疗中心。 先进的诊断和治疗基础设施的提供进一步支持了支配地位。 医院药房还确保有节制地发放高价和专用药品。 本区域越来越多的以医院为基础的泌尿科正在加强分科份额。 该部分受益于综合住院护理和长期治疗监测。
2026至2033年,通过改善处方药的获取途径和增加门诊治疗的采用,零售药店部门预计增长最快,为5.0%。 在零售点增加提供慢性泌尿道药物正在加强病人的方便。 人们对膀胱功能失调管理的认识不断提高,支持在医疗指导下采取自我管理的治疗方法。 整个城市和半城市地区的药店链的扩大正在进一步加快增长。 数字处方服务和电子药用平台也为市场扩张做出了贡献. 然而,农村地区的专门药物供应有限仍然是一个制约因素。
中东和非洲
沙特阿拉伯主导了中东和非洲活动不足的膀胱市场,2025年收入份额最大,为34.28%,辅以强有力的保健基础设施发展、泌尿道护理投资增加,以及越来越多地采用先进的泌尿障碍治疗办法。 该国正在目睹糖尿病、神经疾病和与年龄有关的膀胱功能障碍的日益普遍,这在很大程度上推动了对膀胱管理不足疗法的需求。 扩大医院网络,越来越多地采用药物疗法和最低侵入性程序,以及改善获得诊断性气动测试的机会,都进一步加强了市场渗透。 国家保健改革举措下的持续保健现代化正在加强专家护理的提供和治疗结果。 提高病人和医生对早期诊断的认识也有助于提高治疗率。
沙特阿拉伯未活跃的布拉德市场透视
由于糖尿病、神经疾病和与年龄有关的泌尿功能障碍的日益普遍,加上对高级泌尿护理基础设施的投资不断增加,沙特阿拉伯的膀胱市场呈现出强劲增长。 国家迅速扩张的医院网络和政府主导的保健改革举措正在推动采用药物疗法、神经调节和最低侵入性治疗方案。 此外,对早期诊断的认识得到提高,对泌尿科专家的接触得到改善,这些都有助于提高治疗率。 现代诊断工具和长期膀胱管理方案的日益一体化正在进一步加强第三产业护理中心的市场发展。
南非未活跃的市场透视
南非的膀胱不活跃市场正在稳步增长,其支持是改善获得保健服务的机会,提高对尿道障碍的认识,并增加糖尿病和神经病等慢性病的负担。 该国的公私双重保健系统正在扩大诊断和治疗能力,从而能够更好地识别膀胱功能障碍病例。 越来越多的药物疗法和以康复为基础的治疗办法的采用正在推动市场扩张。 此外,增加对专科诊所和泌尿科的投资正在加强病人护理和推动稳定的市场渗透。
阿拉伯联合酋长国未活跃的布拉德市场透视
由于先进的保健基础设施、高保健支出和大力采用创新医疗技术,阿拉伯联合酋长国的膀胱市场正在稳步扩大。 世界一流的医院和专科泌尿科中心的存在正在推动早期诊断和先进治疗的采用,包括神经调节和最低侵入性程序。 提高病人和医生对膀胱功能失调管理的认识,将进一步支持市场增长。 此外,数字保健解决方案和个性化治疗途径的结合正在改善病人的结果并增强该国的市场地位。
埃及未活跃的布拉德市场透视
埃及的膀胱不活跃市场正在增长,原因是人口糖尿病负担增加,获得专门泌尿道护理的机会有限但有所改善,保健投资增加。 扩大医院基础设施和逐步使诊断能力现代化有助于更好地识别和管理膀胱功能障碍病例。 由于成本效益和可获得性,药物疗法仍然是主要的治疗方法。 此外,政府和私营部门加强专业保健服务的举措正在逐步增加整个城市中心的治疗服务。
中东和非洲未活跃的市场份额
中东和非洲活动不足的膀胱行业主要由历史悠久的公司领导,其中包括:
- Astellas Pharma Inc.(日本)
- 波士顿科学公司(美国)
- 科洛普拉斯公司(丹麦)
- Contratic Group PLC (英国).
- 库克 (美国).
- 霍利斯特公司(美国)
- 布劳恩·塞(德国)
- 梅德罗尼克(爱尔兰)
- Teleflex公司(美国)
- 健康护理(瑞典)
- Laborie医疗技术公司(加拿大)
- 辉瑞股份有限公司(美国)
- AbbVie Inc. (美国).
- 乌罗梅斯(法国)
- Axonics股份有限公司(美国)
- R. Bard, Inc. (美国)
- 奥林匹斯公司(日本)
- Fresenius Medical Care AG(德国)
- Cogentix医疗股份有限公司(美国)
- BD (美国).
中东和非洲的最新事态发展
- 2025年9月,沙特食品药品管理局(SFDA)继续加强先进泌尿道和神经调节技术的医疗器械监管路径,使沙特医院和专科护理中心能更快地采用新型膀胱功能失调管理解决方案.
- 2024年11月,Medtronic在印度推出了其InterSTimTM X系统,并在亚洲和相邻的新兴保健市场提高了对先进神经调节疗法的认识,影响了中东泌尿科中心管理慢性泌尿保留和膀胱活性不足病例的收治趋势.
- 2022年3月,沙特一家第三产业护理中心发布临床证据,显示沙特阿拉伯越来越多地采用圣体神经调节疗法,强调非抑制性泌尿障碍患者的疗效得到改进并强化了地区对高级膀胱功能障碍治疗的接受程度.
- 2022年3月,Axonics获得FDA批准其无充电圣体神经调节系统,强化了阿联酋和沙特阿拉伯私立医院泌尿道部门越来越多地采用的膀胱控制长期疗法,用于膀胱和泌尿道保留管理
- 2021年11月,美德通在全球扩展采用其InterStimTM圣体神经调节平台,强化了泌尿保留和膀胱功能障碍的治疗选择,中东第三护理医院越来越多地采用这些治疗方法,治疗可逆神经性膀胱病例.
SKU-
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 EPIDEMIOLOGY
4.4 THE IMPORTANCE OF UNDERSTANDING PATENTS-
4.4.1 DOXAZOSIN
4.4.2 BETHANECHOL CHLORIDE
4.4.3 TAMSULOSIN HYDROCHLORIDE
4.5 CLINICAL TRIALS FOR UNDERACTIVE BLADDER
4.5.1 EU CLINICAL TRIALS REGISTER-
4.6 MERGER & ACQUISITION IN HEALTHCARE INDUSTRY
4.7 M&A DEALS IN 2021 BY TARGET COMPANY TERRITORY:
4.8 CROSS-BORDER DEALS:
4.9 OUTLOOK FOR 2022:
4.1 PATIENT ENROLMENT STRATEGIES
4.11 FACTORS AFFECTING PATIENT RECRUITMENT:
4.12 CHALLENGES:
4.13 PATIENT FUNNEL ANALYSIS:
4.14 RECOMMENDATIONS
4.14.1 USE OF TECHNOLOGY:
4.14.2 PARTICIPANT CHARACTERISTICS:
4.14.3 RECRUITER CHARACTERISTICS:
4.14.4 SYSTEMS & PROCEDURES:
4.14.5 LOCATION:
4.14.6 NATURE OF RESEARCH:
4.15 CONCLUSION:
4.16 UNDERACTIVE BLADDER PATIENT FLOW DIAGRAM
4.17 WHAT CAUSES UNDERACTIVE BLADDER?
4.17.1 CAUSES OF UNDERACTIVE BLADDER INCLUDE
4.17.2 TESTS TO EVALUATE UNDERACTIVE BLADDER
4.18 UNDERACTIVE BLADDER INVESTIGATIONAL PRODUCTS-
5 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF NEUROGENIC DISORDER
6.1.2 INCREASE IN RESEARCH AND DEVELOPMENT OF UNDERACTIVE BLADDER TREATMENT
6.1.3 FAVOURABLE REIMBURSEMENT SCENARIO
6.1.4 RISING HEALTHCARE EXPENDITURE
6.2 RESTRAINTS
6.2.1 HIGH COST OF RESEARCH AND DEVELOPMENT
6.2.2 STRINGENT GOVERNMENT REGULATIONS ON NEW PRODUCTS APPROVAL
6.3 OPPORTUNITIES
6.3.1 RISING UROLOGIC COMPLICATIONS OF DIABETES
6.3.2 PRESENCE OF NOVEL PIPELINE DRUGS
6.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM
6.4 CHALLENGES
6.4.1 LACK OF PROPER TREATMENT
6.4.2 RISK INVOLVED DURING TREATMENT OF UNDERACTIVE BLADDER
7 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET, BY TYPE
7.1 OVERVIEW
7.2 PHARMACOTHERAPY
7.2.1 ALPHA-BLOCKERS
7.2.2 MUSCARINIC AGONISTS
7.2.3 CHOLINESTERASE INHIBITOR
7.2.3.1 BY DRUGS
7.2.3.1.1 TAMSULOSIN
7.2.3.1.2 DOXAZOSIN
7.2.3.1.3 DISTIGMINE
7.2.3.1.4 BETHANECHOL
7.2.3.1.5 OTHERS
7.2.4 BY PRODUCT TYPES
7.2.4.1 GENERICS
7.2.4.2 BRANDED
7.2.4.2.1 FLOMAX
7.2.4.2.2 ALFADIL
7.2.4.2.3 GRAVITOR
7.2.4.2.4 URIVOID
7.2.4.2.5 OTHERS
7.3 SURGICAL METHODS
7.3.1 SURGICAL NERVE STIMULATION
7.3.2 REDUCTION CYSTOPLASTY
7.3.3 SURGERIES FOR BLADDER OBSTRUCTION
7.3.4 INJECTION INTO EXTERNAL SPHINCTER
7.3.5 OTHERS
7.4 URETHRAL ASSIS DEVICE
7.4.1 INFLOW INTRAURETHRAL VALVE PUMP
7.5 STEM CELL AND GENE THERAPIES
7.5.1 NERVE GROWTH FACTOR
7.5.2 GLIAL-CELL DERIVE NEUTOPHIC FACTORGLIAL
7.5.3 NEUTOPHIN-3 DERIVES FROM GLIALL CELLS
8 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET,BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 PARENTERAL
8.3 ORAL
8.4 OTHERS
9 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET , BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 CLINICS
9.4 ACADEMIC AND RESEARCH
9.5 OTHERS
10 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET , BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 HOSPITAL PHARMACY
10.3 RETAIL PHARMACY
10.4 OTHERS
11 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET, BY REGION
11.1 MIDDLE EAST AND AFRICA
11.1.1 SOUTH AFRICA
11.1.2 SAUDI ARABIA
11.1.3 U.A.E
11.1.4 ISRAEL
11.1.5 EGYPT
11.1.6 KUWAIT
11.1.7 REST OF MIDDLE EAST AND AFRICA
12 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
13 SWOT ANALYSIS
14 COMPANY PROFILES
14.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
14.1.1 COMPANY SNAPSHOT
14.1.2 COMPANY SHARE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.2 PFIZER INC.
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENT
14.3 SUN PHARMACEUTICAL INDUSTRIES LTD.
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 TEVA PHARMACEUTICAL INDUSTRIES LTD
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 NOVARTIS AG
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 DR. REDDY’S LABORATORIES LTD.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENT
14.7 ASTELLAS PHARMA INC.
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 ORION CORPORATION.
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 ALKEM LABS.
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
14.9.4 RECENT DEVELOPMENT
14.1 ALMIRALL, S.A
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.11 AUROBINDO PHARMA.
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 CIPLA INC.
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENT
14.13 GLENWOOD
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 MACLEODS PHARMACEUTICALS LTD.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENT
14.15 ONO PHARMACEUTICAL CO., LTD.
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENT
14.16 VESIFLO, INC.
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
表格列表
TABLE 1 TOTAL 40 DOXAZOSIN DRUGS WERE DISCONTINUED FROM THE MARKET
TABLE 2 TOTAL 38 DOXAZOSIN DRUGS ARE STILL IN THE MARKET
TABLE 3 TOTAL PRESCRIPTION AND DISCONTINUED DRUGS (DOXAZOSIN) BY COMPANY
TABLE 4 TOTAL 58 DRUGS DISCONTINUED
TABLE 5 TOTAL PRESCRIPTION AND DISCONTINUED DRUGS (BETHANECHOL CHLORIDE) BY COMPANY
TABLE 6 OUT OF 3,128 STUDIES ON BLADDER DISORDER, ONLY 22 STUDIES ARE ONGOING FOR THE UAB-
TABLE 7 THESE CLINICAL TRIALS ARE MOSTLY RECRUITING/ONGOING IN DIFFERENT REGIONS OF THE WORLD-
TABLE 8 TOP ACQUISITIONS OF 2021 RANKED BY TOTAL DEAL VALUE:
TABLE 9 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED
TABLE 10 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET, TYPE, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA STEM CELL AND GENE THERAPIES IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET , BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA PARENTERAL IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA ORAL IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET , BY END USER, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA HOSPITALS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA CLINICS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA ACADEMIC AND RESEARCH IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET , BY DISTRIBUTION CHANNEL , 2020-2029 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA HOSPITAL PHARMACY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA RETAIL PHARMACY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 42 MIDDLE EAST AND AFRICA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 43 MIDDLE EAST AND AFRICA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 46 MIDDLE EAST AND AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 47 MIDDLE EAST AND AFRICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 53 SOUTH AFRICA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 SOUTH AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 SOUTH AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 SOUTH AFRICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 57 SOUTH AFRICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 58 SOUTH AFRICA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 59 SOUTH AFRICA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 SOUTH AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 SOUTH AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 62 SOUTH AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 63 SOUTH AFRICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 SOUTH AFRICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 SOUTH AFRICA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 SOUTH AFRICA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 67 SOUTH AFRICA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 68 SOUTH AFRICA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 69 SAUDI ARABIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 70 SAUDI ARABIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 71 SAUDI ARABIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 72 SAUDI ARABIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 73 SAUDI ARABIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 74 SAUDI ARABIA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 75 SAUDI ARABIA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 SAUDI ARABIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 SAUDI ARABIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 78 SAUDI ARABIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 79 SAUDI ARABIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 SAUDI ARABIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 SAUDI ARABIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 SAUDI ARABIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 83 SAUDI ARABIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 84 SAUDI ARABIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 85 U.A.E UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 U.A.E PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 87 U.A.E PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 88 U.A.E BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 89 U.A.E BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 90 U.A.E BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 91 U.A.E BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 U.A.E BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 93 U.A.E BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 94 U.A.E BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 95 U.A.E SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 96 U.A.E URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 U.A.E STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 98 U.A.E UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 99 U.A.E UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 100 U.A.E UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 101 ISRAEL UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 ISRAEL PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 103 ISRAEL PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 ISRAEL BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 105 ISRAEL BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 106 ISRAEL BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 107 ISRAEL BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 108 ISRAEL BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 ISRAEL BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 110 ISRAEL BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 111 ISRAEL SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 112 ISRAEL URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 113 ISRAEL STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 ISRAEL UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 115 ISRAEL UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 116 ISRAEL UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 117 EGYPT UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 118 EGYPT PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 119 EGYPT PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 120 EGYPT BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 121 EGYPT BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 122 EGYPT BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 123 EGYPT BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 EGYPT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 125 EGYPT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 126 EGYPT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 127 EGYPT SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 EGYPT URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 EGYPT STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 130 EGYPT UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 131 EGYPT UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 132 EGYPT UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 133 KUWAIT UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 134 KUWAIT PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 135 KUWAIT PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 136 KUWAIT BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 137 KUWAIT BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 138 KUWAIT BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 139 KUWAIT BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 140 KUWAIT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 141 KUWAIT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 142 KUWAIT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 143 KUWAIT SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 144 KUWAIT URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 145 KUWAIT STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 146 KUWAIT UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 147 KUWAIT UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 148 KUWAIT UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 149 REST OF MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF NEUROGENIC BLADDER INFECTIONS IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET IN THE FORECAST PERIOD
FIGURE 12 TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET
FIGURE 14 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : TYPE, 2021
FIGURE 15 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : TYPE, 2022-2029 (USD MILLION)
FIGURE 16 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : TYPE, CAGR (2022-2029)
FIGURE 17 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : TYPE, LIFELINE CURVE
FIGURE 18 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, 2021
FIGURE 19 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 20 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 21 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 22 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY END USER, 2021
FIGURE 23 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY END USER, 2022-2029 (USD MILLION)
FIGURE 24 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY END USER, CAGR (2022-2029)
FIGURE 25 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY END USER, LIFELINE CURVE
FIGURE 26 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, 2021
FIGURE 27 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 28 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 29 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 30 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET: SNAPSHOT (2021)
FIGURE 31 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021)
FIGURE 32 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2022 & 2029)
FIGURE 33 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021 & 2029)
FIGURE 34 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET: BY TYPE (2022-2029)
FIGURE 35 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
